BiotechTube

Rituxan + CT-P10 + Cyclophosphamide + Vincristine + Prednisone

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lymphoma, Follicular

Conditions

Lymphoma, Follicular

Trial Timeline

Jul 14, 2014 → Dec 29, 2018

NCT ID
NCT02162771

About Rituxan + CT-P10 + Cyclophosphamide + Vincristine + Prednisone

Rituxan + CT-P10 + Cyclophosphamide + Vincristine + Prednisone is a phase 3 stage product being developed by Celltrion for Lymphoma, Follicular. The current trial status is completed. This product is registered under clinical trial identifier NCT02162771. Target conditions include Lymphoma, Follicular.

What happened to similar drugs?

18 of 20 similar drugs in Lymphoma, Follicular were approved

Approved (18) Terminated (0) Active (2)
✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
✅ONTAKEisaiApproved
✅ONTAKEisaiApproved
✅MogamulizumabKyowa KirinApproved
✅IbrutinibJohnson & JohnsonApproved
✅Acalabrutinib capsuleAstraZenecaApproved
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02162771Phase 3Completed

Competing Products

20 competing products in Lymphoma, Follicular

See all competitors
ProductCompanyStageHype Score
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-2416ModernaPhase 2
0
DRL_RI (Proposed rituximab biosimilar)Dr. Reddy's LaboratoriesPhase 3
37
AFM13AffimedPhase 2
25
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
42
EnzastaurinEli LillyPhase 2
35
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + DexamethasoneEli LillyPhase 2
31
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)Eli LillyPhase 2
35
VIP152 + BTKiVincerx PharmaPhase 1
11
Tomivosertib (eFT-508)eFFECTOR TherapeuticsPhase 1/2
14
Nanatinostat in combination with valganciclovirViracta TherapeuticsPhase 2
17
Sepantronium BromideCothera BiosciencePhase 2
29
Copanlisib + RituximabCelltrionPhase 2
39
Rituximab + PembrolizumabCelltrionPhase 2
27
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
31
rituximabCelltrionPhase 1
21
CT-P10 + RituxanCelltrionPhase 3
40
Rituximab, lenalidomideCelltrionPhase 2
42
Rituximab + Lenalidomide + ValemetostatDaiichi SankyoPhase 1/2
39
Valemetostat tosylateDaiichi SankyoPhase 2
39